Niacin, lipids, and heart disease

@article{Malik2003NiacinLA,
  title={Niacin, lipids, and heart disease},
  author={Shaista Malik and M. Kashyap},
  journal={Current Cardiology Reports},
  year={2003},
  volume={5},
  pages={470-476}
}
Niacin is the most effective medication in current clinical use for increasing high-density lipoprotein (HDL) cholesterol. It has the broadest effect on the lipid profile, reducing all atherogenic apolipoprotein (apo) B and increasing all antiatherogenic apo AI-containing lipoproteins, resulting in significant reduction in atherosclerotic complications and total mortality in trials. Recent research indicates novel major target sites of action in the liver to 1) directly inhibit diacylglycerol… Expand
Niacin therapy in atherosclerosis
TLDR
New data indicate that niacin alters lipoprotein metabolism in novel ways, and mediates other beneficial nonlipid changes that may be atheroprotective, forming the rationale for the use of niac in combination with agents possessing complementary mechanisms of action for cardiovascular risk reduction beyond that observed with monotherapy. Expand
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
TLDR
The goal of this review is to discuss the therapeutic potential of synthetic apoA-I mimetic peptides that have undergone initial clinical assessment and discuss newer apoE mimetics that mediate the clearance of atherogenic lipids from the circulation and possess anti-inflammatory properties. Expand
HDL therapy for cardiovascular diseases: the road to HDL mimetics
TLDR
The goal of this review is to discuss the current status of HDL therapeutics, with emphasis on a novel class of agent, the apolipoprotein A-I mimetic peptides, which improve the functional properties of HDL cholesterol. Expand
Novel LDL-oriented pharmacotherapeutical strategies.
TLDR
Alternative drugs monotherapy or in combination with statins will be sufficient to reduce cholesterol concentrations to optimal levels, and a new era for better LDL-C managements is plausible. Expand
Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects.
TLDR
High expression of niacin receptor in a variety of immune cell types, lowering of inflammatory markers, and beneficial impact on adipokines expression could provide rational to the hypothesis that anti-inflammatory effect is also an important property of niakin on atherosclerosis beyond its lipid-altering effects. Expand
Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
TLDR
The antiatherogenic effects of HDL, recent insights into the mechanisms of action of currently available, and emerging HDL-based therapies are reviewed, showing that increasing total HDL cholesterol may not be as important as increasing the functional properties of HDL. Expand
Pharmacogenomics of cholesterol-lowering therapy.
TLDR
In the future, pharmacogenomic testing may allow risk stratification of patients to avoid serious side effects and enable clinicians to select lipid-lowering drugs with the highest efficacy resulting in the best response to therapy. Expand
Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection
TLDR
Cardiovascular disease treatment and prevention can be improved by combining current low-density lipoprotein-based strategies with effective HDL-based interventions, and novel interventions that mimic HDL’s beneficial effects are proving beneficial in animal and human studies. Expand
Recent developments in modulating atherogenic lipoproteins
TLDR
Several new classes of drug are undergoing clinical evaluation that show promise for atherogenic lipoprotein reduction in patients who are statin intolerant, including inhibitors of ATP citrate lyase and proprotein convertase subtilisin/kexin type 9. Expand
Effect of Niacin on High-Density Lipoprotein Apolipoprotein A-I Kinetics in Statin-Treated Patients With Type 2 Diabetes Mellitus
TLDR
The effect on HDL metabolism was independent of the reduction in plasma triglyceride with ER niacin treatment, and whether this finding applies to other dyslipidemic populations remains to be investigated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
The benefits of niacin in atherosclerosis
TLDR
Emerging evidence indicates that niacin can be used effectively and safely in patients with type 2 diabetes mellitus, who often have low HDL levels. Expand
Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol
TLDR
The data indicate that unlike gemfibrozil, niacin selectively increases LP-AI compared withLP-AI+AII particle concentration in patients with low HDL-C levels, suggesting an additional mechanism by which niacIn mediates its antiatherogenic properties. Expand
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
TLDR
Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels, and the use of antioxidant vitamins in this setting must be questioned. Expand
A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
TLDR
A cholesterol-modifying effect of Niaspan is demonstrated consistent with those reported for niacin, but demonstrated a better tolerance for flushing. Expand
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
TLDR
In patients with atherogenic dyslipidemia, both drugs had important effects on lipoprotein subfractions, which contributed to a reduction in coronary heart disease risk, and both drugs equally reduced VLDL subclass levels. Expand
Mechanism of action of niacin on lipoprotein metabolism
TLDR
Current evidence indicates that the post-translational apo-B degradative processes regulate the hepatic assembly and secretion of VLDL and the subsequent generation of LDL particles, which are precursors for the formation of more buoyant or small, dense LDL particles by lipid transfer protein- and hepatic lipase-mediated processes. Expand
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
TLDR
Low doses of ER niacin (1000 or 1500 mg/d) are a treatment option for dyslipidemia in patients with type 2 diabetes and no hepatotoxic effects or myopathy were observed. Expand
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
TLDR
This long-term study confirms the earlier short-term findings that Niaspan is safe and effective as monotherapy in plasma lipoprotein regulation and indicates that the decrease in phosphorus is a new finding in niacin therapy. Expand
A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
TLDR
The IR niacin is preferred for the management of hypercholesterolemia but can also cause significant adverse effects and should be given only to patients who can be carefully monitored by experienced health professionals. Expand
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
TLDR
In patients with a low baseline HDL-C level, Niaspan at its higher doses provided up to 2-fold greater LDL-C increases, decreases in lipoprotein(a), improvements inlipoprotein cholesterol ratios, and lower fibrinogen levels compared with gemfibrozil. Expand
...
1
2
3
4
5
...